Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Lexicon’s IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial

July 28, 2011 By Bio-Medicine.Org

THE WOODLANDS, Texas, July 28, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX
), a biopharmaceutical company focused on discovering
breakthrough treatments for human disease, announced today that it
has successfully completed a Phase 1 clinical trial of LX1033, an
orally-delivered small molecule drug candidate for
diarrhea-predominant
irritable bowel syndrome (IBS-d).  Lexicon plans to move
LX1033 forward into a Phase 2 study in patients with IBS-d.

Top-line results demonstrated that LX1033 was well tolerated at
all doses and produced a statistically significant reduction in
serotonin synthesis compared to placebo, as measured by both plasma
(p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid
(5-HIAA), a biomarker for serotonin synthesis. Importantly, a
greater reduction in serotonin synthesis was achieved with lower
and less frequent dosing and at lower drug exposure levels than was
observed with Lexicon’s first generation serotonin synthesis
inhibitor, LX1031, which had previously demonstrated clinical
benefit to IBS patients in a Phase 2a clinical trial as measured by
both global assessment of adequate relief and stool
consistency.

“Based on the completed LX1033 Phase 1 program, we are confident
that a convenient dose regimen of this compound can provide the
level of serotonin reduction that we have previously associated
with clinical benefit for patients with IBS-d,” said Dr. Brian
Zambrowicz, chief scientific officer at Lexicon.  “We were
also impressed by the performance of the blood test for measuring
5-HIAA and anticipate using this biomarker to guide future drug
development of LX1033.”

The LX1033 Phase 1 trial was conducted as a

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech